[UnitedHealthCare]’s decision to give Amgen Inc.’s Neulasta preferred formulary status over pegfilgrastim biosimilars in return for a significant rebate is getting attention as US policymakers consider ways to promote uptake of biosimilars and reduce drug costs.
Beginning July 1 in UnitedHealthCare's commercial and community plans, use of Neulasta Onpro or Neulasta in a vial will be...







